Brief: Allergy Therapeutics Announces Positive Interim Analysis Data From Phase I/Iia Vlp Peanut Protect Trial
04/12/2024 07:18
Dec 4 (Reuters) - Allergy Therapeutics PLC AGY.L :
* ALLERGY THERAPEUTICS PLC: ANNOUNCES POSITIVE INTERIM
ANALYSIS
DATA FROM PHASE I/IIA VLP PEANUT PROTECT TRIAL
Source text: ID:nRSD6783Oa
Further company coverage: AGY.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allergy Therapeutics
See all newsBrief: Allergy Therapeutics Expects FY 2026 Revenue Of £59.90 Million, Up 9% Reported
UK's Allergy Therapeutics FY revenue beats on Grassmuno launch
Allergy Therapeutics - Trading update for the year ended 30 June 2026
Brief: Allergy Therapeutics Appoints Helge Weiner-Trapness As Executive Chairman
Allergy Therapeutics - Appointment of Executive Chairman